Exelixis

Exelixis Tangible Book Value per Share

The Tangible Book Value per Share of Exelixis (EXEL) as of Oct 31, 2026 is 7.44 USD. In the previous year, Tangible Book Value per Share was 7.74 USD — a change of -3.80% (lower).

Tangible Book Value per Share

7.44USD

YoY

-3.80%

Last updated:

Tangible Book Value per Share of Exelixis is 2025 7.44 USD. Tangible Book Value per Share of Exelixis was 2024 7.74 USD. It decreases by -3.80% lower compared to the previous year.

The Exelixis Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
4.34 USD
Jan 1, 2019
5.76 USD
Jan 1, 2020
6.44 USD
Jan 1, 2021
7.62 USD
Jan 1, 2022
8.60 USD
Jan 1, 2023
7.81 USD
Jan 1, 2024
7.74 USD
Jan 1, 2025
7.44 USD
The Exelixis Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
7.44USD-3.80%
7.74USD-0.90%
7.81USD-9.26%
8.60USD+12.94%
7.62USD+18.26%
6.44USD+11.91%
5.76USD+32.56%
4.34USD+453.05%
0.79USD+763.22%
0.09USD-115.26%
-0.60USD-5.90%
-0.63USD-4,756.86%
0.01USD-98.93%
1.27USD-147.42%
-2.67USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Tangible Book Value per Share of Exelixis is 7.44 USD in 2025.

Tangible Book Value per Share of Exelixis changed from 7.74 USD to 7.44 USD, representing a -3.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Exelixis since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Exelixis

All Key Metrics — Exelixis